cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Kalvista Pharmaceuticals Inc
11 watching
Current Price
$7.87
$0.25
(3.28%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
193.62M
52-Week High
52-Week High
17.345
52-Week Low
52-Week Low
4.12
Average Volume
Average Volume
0.23M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization193.62M
icon52-Week High17.345
icon52-Week Low4.12
iconAverage Volume0.23M
iconDividend Yield--
iconP/E Ratio--
What does the Kalvista Pharmaceuticals Inc do?
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company s product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which has completed Phase II clinical trial for an oral on-demand therapy for acute HAE attacks; and KVD824, an oral product candidate for the treatment of HAE. The company is headquartered in Cambridge, Massachusetts.
Read More
How much money does Kalvista Pharmaceuticals Inc make?
News & Events about Kalvista Pharmaceuticals Inc.
Business Wire
1day ago
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will be presenting at the SVB Securities Global Biopharma Conference (virtual) on...
Business Wire
1month ago
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it has entered into a subscription agreement with institutional investors to sell, in...
Zolmax
2 months ago
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV Get Rating) was the recipient of a significant decrease in short interest during the month of November. As of November 15th, there was short interest totalling 2,080,000 shares, a decrease of 8.8% from the October 31st total of 2,280,000 shares. Based on ...
Benzinga
4 months ago
Losers read more...
Business Wire
4 months ago
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2022 HAE International (HAEi) Global...
Frequently Asked Questions
Frequently Asked Questions
What is Kalvista Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Kalvista Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Kalvista Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Kalvista Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Kalvista Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Kalvista Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Kalvista Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Kalvista Pharmaceuticals Inc?
plus_minus_icon
What percentage is Kalvista Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Kalvista Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$7.87
$0.25
(3.28%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00